Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]

Targeting JAK-STAT pathway in malignant and non-malignant cells in...

Dr Ross Levine - Memorial Sloan-Kettering Cancer Center, New York, USA

Targeting JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative neoplasms ( Dr Ross Levine - Memorial Sloan-Kettering Cancer Center, New York, USA )

Addition of obinutuzumab or rituximab to chlorambucil for chronic lymphocytic...

Dr Valentin Goede - University Hospital of Cologne, Germany

Addition of obinutuzumab or rituximab to chlorambucil for chronic lymphocytic leukaemia ( Dr Valentin Goede - University Hospital of Cologne, Germany )

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma

Prof Heinrich Lokhorst - Universitair Medisch Centrum Utrecht, Heidelberglaan...

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma ( Prof Heinrich Lokhorst - Universitair Medisch Centrum Utrecht, Heidelberglaan, Netherlands )

Vemurafenib and ipilimumab for metastatic melanoma

Dr Caroline Robert - Institute Gustave Roussy, Paris, France

Vemurafenib and ipilimumab for metastatic melanoma ( Dr Caroline Robert - Institute Gustave Roussy, Paris, France )

Phase I study measures effect of ipilimumab and nivolumab combination in...

Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Phase I study measures effect of ipilimumab and nivolumab combination in melanoma patients ( Prof Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )

Comment on progression free survival in lung cancer patients and the GALAXY-1...

Dr Marjorie G. Zauderer - Memorial Sloan-Kettering Cancer Center, New York, USA

Comment on progression free survival in lung cancer patients and the GALAXY-1 trial ( Dr Marjorie G. Zauderer - Memorial Sloan-Kettering Cancer Center, New York, USA )

Paclitaxel dosing equally effective in preventing breast cancer progression

Dr Andrew Seidman - Memorial Sloan-Kettering Cancer Center, New York, USA

Paclitaxel dosing equally effective in preventing breast cancer progression ( Dr Andrew Seidman - Memorial Sloan-Kettering Cancer Center, New York, USA )

Paclitaxel chemotherapy schedules equally effective for early-stage breast...

Dr G. Thomas Budd - Cleveland Clinic, Cleveland, USA

Paclitaxel chemotherapy schedules equally effective for early-stage breast cancer ( Dr G. Thomas Budd - Cleveland Clinic, Cleveland, USA )

Nintedanib in combination with standard second line therapy in lung cancer

Dr Martin Reck - Hospital Grosshansdorf, Wohrendamm, Germany

Nintedanib in combination with standard second line therapy in lung cancer ( Dr Martin Reck - Hospital Grosshansdorf, Wohrendamm, Germany )

Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for...

Dr Suresh S. Ramalingam - Emory University, Atlanta, USA

Ganetespib inhibits Hsp90 effective as second-line therapy with docetaxel for advanced lung cancer ( Dr Suresh S. Ramalingam - Emory University, Atlanta, USA )

Axillary radiotherapy provides alternative to invasive early stage breast...

Dr Emiel J. Rutgers - Netherlands Cancer Institute, Amsterdam

Axillary radiotherapy provides alternative to invasive early stage breast cancer surgery ( Dr Emiel J. Rutgers - Netherlands Cancer Institute, Amsterdam )

Paclitaxel chemotherapy schedules are equally effective for early-stage breast...

Dr G. Thomas Budd - MD Cleveland Clinic, USA

Paclitaxel chemotherapy schedules are equally effective for early-stage breast cancer ( Dr G. Thomas Budd - MD Cleveland Clinic, USA )

More from ecancer